NASH Companies Take The Stage At AASLD
AASLD Round-Up: NGM, Inventiva, Albireo Among The Companies Progressing In NASH
Executive Summary
NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.
You may also be interested in...
Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Akero Looks To Accelerate Path To Pivotal NASH Data With Phase IIb/III Protocol
Akero gets FDA’s ok to conduct Phase IIb/III study of FGF21 analog efruxifermin in biopsy-confirmed non-alcoholic steatohepatitis patients. With NASH leadership up in the air, Akero, 89bio and other FGF analog sponsors jockey for top spot.
Albireo Exits NASH, But Has Best-In-Class IBAT Opportunity
Elobixibat demonstrated ability to reduce LDL cholesterol but is being discontinued in NASH due to its unspectacular overall profile. The firm is staying focused on odevixibat, which could be best-in-class for pediatric liver indications, analysts say.
Need a specific report? 1000+ reports available
Buy Reports